Iacob Speranta, Ghioca Mihaela, Csiki Irma Eva, Tomescu Dana, Droc Gabriela, Hrehoret Doina, Brasoveanu Vlad, Pietrareanu Corina, Iacob Razvan, Gheorghe Cristian, Popescu Irinel, Gheorghe Liana
Center for Digestive Diseases and Liver Transplantation, Fundeni Clinical Institute.
"Carol Davila" University of Medicine and Pharmacy.
Medicine (Baltimore). 2020 Oct 30;99(44):e22419. doi: 10.1097/MD.0000000000022419.
Acute on chronic liver failure (ACLF) is a dynamic syndrome, but frequently associated with a high 1 month mortality rate. This is the first study applying the new European Association for the Study of the Liver- chronic liver failure consortium criteria to explore mortality on the waiting list (WL) and early after liver transplantation (LT) in a cohort of Romanian cirrhotic patients that improved or recovered after an episode of ACLF.To assess frequency and waitlist mortality for different grades of ACLF.An observational study was conducted; 257 patients with liver cirrhosis included on the WL between 2015 and 2017 were analyzed. The cumulative incidence of waitlist mortality or removal was calculated for combination of competing events using multivariable competing risks regression.ACLF-1 occurred in 12.07%, ACLF-2 in 7.39% and ACLF-3 in 8.56% of patients. Median Model for End Stage Liver Diseases (MELD) score at the moment of ACLF was 29. The main event while on the WL was death, followed by ACLF; patients with ACLF-3 had a significantly greater subhazard ratio for mortality of 2.25 (1.55-3.26) compared to patients with ACLF-1 or 2. LT proved to be associated with a significantly lower risk of death on the WL at 6 months after inclusion. One and 12 months post-transplant survival of patients with or without ACLF was similar (P = .77).Occurrence of an ACLF episode while on the WL is associated with a significantly high mortality rate, as well as MELD score at inclusion on the WL, renal and liver failure, presence of hepatic encephalopathy. Overall patient short and long term survival after LT is similar to non-ACLF patients in good selected cases.
慢加急性肝衰竭(ACLF)是一种动态综合征,但常伴有较高的1个月死亡率。这是第一项应用新的欧洲肝脏研究协会-慢性肝衰竭联盟标准,在一组经历ACLF发作后病情改善或恢复的罗马尼亚肝硬化患者队列中,探讨等待名单(WL)上以及肝移植(LT)后早期死亡率的研究。为评估不同等级ACLF的发生率和等待名单死亡率。开展了一项观察性研究;分析了2015年至2017年间纳入WL的257例肝硬化患者。使用多变量竞争风险回归计算竞争事件组合的等待名单死亡率或移除的累积发生率。12.07%的患者发生ACLF-1,7.39%发生ACLF-2,8.56%发生ACLF-3。ACLF发生时终末期肝病模型(MELD)评分中位数为29。在WL期间的主要事件是死亡,其次是ACLF;与ACLF-1或2的患者相比,ACLF-3的患者死亡的亚风险比显著更高,为2.25(1.55-3.26)。LT被证明与纳入后6个月时WL上显著较低的死亡风险相关。有或无ACLF的患者移植后1个月和12个月的生存率相似(P = 0.77)。在WL期间发生ACLF发作与显著较高的死亡率相关,以及与WL纳入时的MELD评分、肾和肝功能衰竭、肝性脑病的存在有关。在精心挑选的病例中,LT后患者的总体短期和长期生存率与非ACLF患者相似。